Abbott's Galectin-3 Test Provides Doctors in Europe with New Tool for Assessing the Prognosis of Chronic Heart Failure Patients

Wed Apr 10, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link

Galectin-3 test may help physicians identify patients at highest risk for a
worse prognosis, including re-hospitalization and death, allowing them to tailor
the level of care to individual patient needs1
ABBOTT PARK, Ill.,  April 10, 2013  /PRNewswire/ -- Abbott today announced CE
Marking (Conformite Europeenne) for the ARCHITECT Galectin-3 assay, a test to
aid doctors in assessing the prognosis of patients diagnosed with chronic heart
failure (HF). The test was developed in partnership with BG Medicine, Inc.,
(NASDAQ: BGMD) to run on Abbott's ARCHITECT immunochemistry platform.  

"Galectin-3 reflects the pathophysiology of heart failure and is one of the most
powerful prognostic indicators in heart failure. It helps clinicians identify
which patients are at high risk for worsening heart failure early in the course
of their disease," said Dr.  Rudolf de Boer, Associate Professor in Cardiology
at the University Medical Centre Groningen,  the Netherlands. "Knowing which
patients are at increased risk of hospital readmission - independent of other
variables - could provide physicians with important information to help them
reach different decisions about treatment, which may benefit patient care."

Heart failure, or the inability of the heart to circulate blood effectively, is
associated with poor patient outcomes, a lower quality of life, and recurrent
and costly health services.2, 3 While the progress of HF is different for each
patient, several studies demonstrate that HF patients with higher levels of a
protein called galectin-3 present are more likely to have worse outcomes,
including re-hospitalization and death.4

"Despite numerous medical advances, the number of deaths among hospitalized
heart failure patients remains high, exceeding that of most cancers," said 
Brian Blaser, executive vice president, Diagnostics Products, Abbott. "The new
ARCHITECT Galectin-3 test is a helpful tool to aid physicians in their care of
these critically ill patients."

The ARCHITECT Galectin-3 test is available in several European countries.  

Intended Use
The ARCHITECT Galectin-3 assay is a chemiluminescent microparticle immunoassay
(CMIA) for the quantitative determination of galectin-3 in human serum and EDTA
plasma on the ARCHITECT  i  System. The ARCHITECT Galectin-3 assay may be used
in conjunction with clinical evaluation as an aid in assessing the prognosis of
patients diagnosed with chronic heart failure.  

About BG Medicine
BG Medicine, Inc., (Nasdaq: BGMD) is a diagnostics company focused on the
development and commercialization of novel cardiovascular tests to address
significant unmet medical needs, improve patient outcomes and reduce healthcare
costs. The Company has two products: the BGM Galectin-3®  test for use in
patients with chronic heart failure is available in  the United States  and 
Europe; and the CardioSCORE test for the risk prediction of major cardiovascular
events will be launched in  Europe  in the first half of 2013.  

For additional information about BG Medicine, heart failure and galectin-3
testing, please visit  and

About Abbott Diagnostics
Abbott is a global leader in  in vitro  diagnostics and offers a broad range of
innovative instrument systems and tests for hospitals, reference labs, molecular
labs, blood banks, physician offices and clinics. With more than 22,000
customers in more than 100 countries, Abbott's diagnostic products offer
customers automation, convenience, bedside testing, cost-effectiveness, and
flexibility. Abbott has helped transform the practice of medical diagnosis from
an art to a science through the company's commitment to improving patient care
and lowering costs.

About Abbott
Abbott is a global healthcare company devoted to improving life through the
development of products and technologies that span the breadth of healthcare.
With a portfolio of leading, science-based offerings in diagnostics, medical
devices, nutritionals and branded generic pharmaceuticals, Abbott serves people
in more than 150 countries and employs approximately 70,000 people.   

Visit Abbott at  and connect with us on Twitter at @AbbottNews.

1  de Boer, R, Voors, A, Muntendam, P, et al. Galectin-3: A novel mediator of
heart failure development and progression. European Journal of Heart Failure
2009; 11: 811-817.
2 McMurray, JJV, Adamopoulos, S, Anker, SD et al. ESC Guidelines for the
diagnosis and treatment of acute and chronic heart failure 2012. European Heart
Journal. 2012; 33: 1787-1847.
3  Mosterd, A, Hoes, AW. Clinical Epidemiology of Heart Failure. Heart. 2007;
4  de Boer, R, Lok, D, Jaarsma, T, et al. Predictive value of plasma galectin-3
levels in heart failure with reduced and preserve ejection fraction. Annals of
Medicine 2011; 43: 60-68.

SOURCE  Abbott

Darcy Ross, (847) 937-3655; Jessica Masuga, (847) 935-0650; Financial:Tina
Ventura, (847) 935-9390

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.